FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy
You may also be interested in...
Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel
Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel
Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel
Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel
Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel
FDA's Orthopedic and Rehabilitation Devices panel will meet Aug. 19 to assess Q-Med's PMA application for its Durolane single-injection, hyaluronic acid-based treatment for knee osteoarthritis